NSCLC

This study tests whether adding the immunotherapy drug durvalumab to precise radiation therapy (SBRT) can better control early-stage non-small cell lung cancer compared to radiation alone. About 13 adults with stage I to IIIA lung cancer received the combination. The main goal is…

This study offers continued treatment with lorlatinib for people with ALK- or ROS1-positive non-small cell lung cancer who are already benefiting from it in earlier Pfizer studies. The goal is to keep providing the drug while collecting more safety information. About 76 participa…

This study tests a new combination of drugs (datopotamab deruxtecan, durvalumab, and carboplatin) against the current standard treatment for advanced non-small cell lung cancer that doesn't have certain gene changes. About 1,350 adults with stage IIIB, IIIC, or IV lung cancer wil…

This phase 2 trial studied 156 people with advanced EGFR-mutant lung cancer to find the best time to start the drug osimertinib. Some received it right away, while others started with a different drug and switched to osimertinib when a blood test showed a resistance marker. The s…

This early-stage study tests an experimental drug called CLN-619, given alone or with pembrolizumab, in adults with advanced solid tumors (including non-small cell lung cancer). The main goals are to check safety and see if the drug shrinks tumors. About 440 participants will be …

This study tests a daily pill called furmonertinib in about 100 people with advanced lung cancer that has a specific genetic change (EGFR exon 20 insertion) and has worsened after chemotherapy. The goal is to see if the drug can shrink tumors and control the disease. Participants…

This study looks at whether it is safe to continue the targeted cancer drug osimertinib while also giving radiation therapy to people with advanced EGFR-positive non-small cell lung cancer. The goal is to control tumors that start growing again during treatment. About 42 adults a…

This early-phase study tests a new drug called LP-184 in 64 adults with advanced solid tumors (like pancreatic, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their …

This study tests whether combining the drug durvalumab with radiation therapy can slow down lung cancer growth in people with stage II or III non-small cell lung cancer. Unlike standard treatment, this approach skips chemotherapy. The goal is to see if more patients stay cancer-f…

This study looks at whether giving precise radiation (SBRT) to tumors that have just started to grow can help people with metastatic triple-negative breast cancer or non-small cell lung cancer live longer without their disease getting worse. About 107 adults are taking part. The …

This study tests the drug brigatinib in people with a specific type of advanced lung cancer called ALK-positive non-small cell lung cancer. The goal is to see how well the drug controls the disease and delays tumor growth. About 118 adults with stage III or IV cancer that cannot …

This study tests whether adding high-dose vitamin C (ascorbate) to the usual treatment of radiation and chemotherapy (carboplatin and paclitaxel) helps control non-small cell lung cancer. About 43 participants received this combination therapy. The goal is to see if the vitamin C…

This early-stage study tests a new drug called IOA-244 in about 210 adults with advanced or metastatic cancers, including lung cancer, melanoma, and lymphoma. The main goal is to see if the drug is safe and tolerable, both alone and with other treatments. Researchers also want to…

This study tests a new drug called cadonilimab (AK104) combined with standard chemotherapy and radiation for people with stage III lung cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and control the disease. Participants receive…

This phase II study tests a new drug called AK112 (a bispecific antibody that targets PD1 and VEGF) combined with standard chemotherapy in 265 people with advanced non-small cell lung cancer (stage IIIB/C or IV). The goal is to see if the combination shrinks tumors and how safe i…

This early-phase study tests whether adding low dose radiation and focused radiation (SBRT) to immunotherapy can be safe for people with advanced non-small cell lung cancer who have run out of standard options. Nine participants will receive the combination treatment at one hospi…

This study tests giving chemotherapy plus the immunotherapy drug nivolumab before surgery to people with a rare type of lung cancer called Pancoast tumor. The goal is to see if this combination can shrink the tumor enough to allow complete removal. After surgery, patients may rec…

This study offers continued treatment with avelumab for people with advanced cancers like lung, ovarian, or bladder cancer who are already benefiting from it in earlier Pfizer studies. The goal is to keep providing the drug and monitor safety and survival. About 68 participants w…

This study tests an experimental drug called JAB-21822 (glecirasib) in people with advanced solid tumors that have a specific KRAS G12C mutation and have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it shrinks…

This study tests whether adding a special type of radiotherapy to standard chemotherapy and immunotherapy before surgery can help people with stage III lung cancer live longer without the cancer coming back. About 90 participants will receive one of three different radiation sche…

This study tests an experimental daily pill, BDTX-1535, in about 200 adults with advanced non-small cell lung cancer or glioblastoma (a type of brain tumor). The drug targets specific EGFR mutations that make cancers resistant to other treatments. The goal is to find the safest d…

This study tests whether adding the chemotherapy drug S-1 to the targeted therapy osimertinib can shrink tumors in people with EGFR-mutant lung cancer that has stopped responding to treatment. About 30 adults with advanced lung cancer will receive the combination and be monitored…

This early-stage trial tests a combination of two experimental drugs, defactinib and VS-6766, in people with advanced solid tumors that have not responded to standard treatments. The study includes patients with certain lung, ovarian, endometrial, or pancreatic cancers. The main …

This study tests a daily pill called lazertinib in 150 people with advanced non-small cell lung cancer that has specific EGFR mutations. The goal is to see how well it controls the cancer and delays its growth, and to understand why resistance might develop. Participants take the…

This early-stage study tests a new oral drug, furmonertinib mesilate, in 30 people with advanced non-small cell lung cancer that has a specific EGFR mutation (exon 20 insertion). The drug aims to shrink or control tumors. Participants include both those who have had prior treatme…

This early-stage trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in 120 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find safe doses and check for side effects, while also measur…

This early-stage study tests a new drug called TT125-802 in about 50 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety and find the best dose. Researchers will also watch for any tumor shrinkage an…

This study offers continued access to the drug crizotinib for people with certain cancers (NSCLC, ALCL, or IMT) who are already benefiting from it in another Pfizer study that is ending. About 27 participants will be enrolled to receive ongoing treatment and to monitor safety. Th…

This study looks at whether a blood test (liquid biopsy) can help doctors see how well the drug brigatinib is working in people with a specific type of advanced lung cancer (ALK-positive NSCLC). About 33 patients will take brigatinib pills and give blood samples over time. The go…

This study looks at whether giving the drug serplulimab together with chemotherapy before surgery can help people with a certain type of lung cancer (non-small cell lung cancer). The goal is to shrink tumors and make surgery more effective, possibly reducing the chance of cancer …

This study tests an experimental oral drug, MRT-2359, in people with certain advanced cancers, including lung cancer and lymphoma, that are driven by MYC genes. The trial has two phases: first, finding a safe dose, and second, checking if the drug shrinks tumors. About 174 adults…

This study tests whether adding an extra immunotherapy drug (tiragolumab) to standard chemo, radiation, and atezolizumab can help people with stage III lung cancer live longer without the disease getting worse. About 178 adults with newly diagnosed, inoperable stage III NSCLC wil…

This study tests a new pill, poziotinib, against standard chemotherapy (docetaxel) in people with advanced lung cancer that has a specific genetic change (HER2 mutation). The goal is to see if poziotinib can keep tumors from growing longer than chemo. About 268 adults who have al…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy after lung cancer surgery can clear tiny bits of tumor DNA from the blood. About 100 adults with early-stage non-small cell lung cancer who had surgery and still have detectable tumor DNA…

This study looks at using radiofrequency ablation (RFA), a treatment that uses heat to destroy tumors, for people with lung cancer or tumors that have spread to the lungs. It includes 72 patients who cannot have surgery due to other health issues or who choose not to. The goal is…

This study looks at whether a blood test can quickly and accurately find certain gene changes in people with advanced lung cancer or melanoma. These gene changes help doctors choose the right targeted therapy. The goal is to see if this blood-based method works as well as the sta…

This study looks at adults with certain cancers (like lung, breast, kidney, or melanoma) that have spread to the brain. All participants are also receiving immunotherapy. The goal is to see if giving a lower dose of radiation over a few days causes fewer side effects than the sta…

This study looks at whether a simple blood test can find tiny bits of cancer DNA left in the body after lung cancer surgery. Researchers will follow 133 people with early-stage lung cancer for one year to see if the test results match who has a relapse. The goal is to learn if th…

This study follows about 400 adults who previously received A2Bio gene therapy for various solid tumors, including lung, colon, and pancreatic cancers. The main goal is to track long-term safety and see how well the treatment effects last over time. Participants do not receive ne…

This study tests new treatments for non-small cell lung cancer given before surgery. The goal is to see which treatments shrink tumors the most, helping doctors choose the best options for future patients. Only 4 people took part, so results are very early.

This study follows 330 people with non-small cell lung cancer who receive immunotherapy before surgery. Researchers measure cortisol levels at different times to see if changes in this stress hormone relate to how well the tumor responds to treatment. The goal is to find a simple…

This study looks at how doctors manage and treat people with a specific type of advanced lung cancer (ALK-positive NSCLC) using the drug alectinib in real-world clinics. Researchers will track about 800 patients to see how long the treatment works, what treatments are used next, …

This study aims to understand why some people under 50 develop lung cancer by looking at their lifestyle, environment, and genetics. Participants complete online surveys and may donate blood. The goal is to find patterns that could help prevent or catch the disease earlier.